As we delve deep into countless medical journals to uncover the latest on Integrative Medicine’s approach to kidney health, we are always reminded of the value of your time. Our commitment remains steadfast in curating and succinctly summarizing these vital studies for you. Welcome to the July Research and News.
Nutrition in Kidney Health
Vitamin K2 Slows the Progression of Coronary Artery Calcification
In this randomized, placebo-controlled clinical trial, 180 adults with established coronary artery disease and moderate coronary artery calcification received either 360 µg of vitamin K2 (menaquinone-7, MK-7) or placebo daily for two years.
Patients taking MK-7 experienced significantly slower progression of coronary artery calcification compared with placebo. The benefit appeared to result from slowing the calcification of previously non-calcified plaques.
The supplement was well tolerated, and no significant adverse effects were reported.
Why Is This Important?
Vascular calcification is a major contributor to cardiovascular disease and is especially common in people with chronic kidney disease.
This is one of the first randomized trials to demonstrate that long-term vitamin K2 supplementation can slow the progression of coronary artery calcification in patients with coronary artery disease.
Although the study did not evaluate heart attacks or survival, it strengthens the growing evidence that vitamin K plays an important role in vascular health.
Larger clinical trials are still needed to determine whether slowing calcification ultimately translates into fewer cardiovascular events, particularly in patients with CKD, who are at especially high risk of vascular calcification.
A New Pathway Could Reduce Treatment Side Effects in ADPKD
This study identified a previously unknown mechanism by which the kidney regulates water reabsorption independently of vasopressin.
The researchers found that intracellular uric acid (urate) in collecting duct cells influences the movement of aquaporin-2 (AQP2) water channels to the cell surface through a GLUT9b–ABCG2–AMPK signaling pathway.
In mouse models of autosomal dominant polycystic kidney disease (ADPKD), inhibiting the urate transporter ABCG2 with probenecid reduced the excessive urine output caused by tolvaptan while preserving its ability to slow cyst growth.
A small Phase 2 clinical trial in patients with ADPKD similarly showed that adding probenecid reduced daily urine volume and nighttime urination.
Why is this important?
Excessive thirst and polyuria are the leading reasons patients discontinue tolvaptan, the only FDA-approved therapy that slows ADPKD progression.
This study suggests that targeting urate transport may reduce these bothersome side effects without compromising the drug’s effectiveness.
If confirmed in larger clinical trials, combining probenecid or other modulators of this newly identified urate–AMPK–AQP2 pathway with tolvaptan could improve treatment adherence and quality of life for patients with ADPKD.
Genetics and Epigenetics
A Repurposed Drug May Turn Down the Kidney Fibrosis Switch
This experimental study explored whether 17-DMAG, a heat shock protein 90 inhibitor, could reduce kidney fibrosis. Kidney fibrosis is the scarring process that drives chronic kidney disease progression.
The researchers found that 17-DMAG lowered levels of METTL3, a molecule that helps activate and stabilize pro-fibrotic gene programs.
In kidney cells and mouse models of fibrosis, treatment with 17-DMAG reduced METTL3 activity, decreased abnormal RNA methylation signals, lowered collagen buildup, and reduced fibrosis markers.
Mechanistically, the drug activated a protective heat shock response that ultimately suppressed c-Jun signaling, leading to lower METTL3 expression.
Why is this important?
Fibrosis is the common final pathway of many kidney diseases, but there are few therapies that directly target it. This study suggests that blocking the HSP90–c-Jun–METTL3 pathway may help shut down the molecular machinery that promotes kidney scarring.
Although this is still early preclinical work, it identifies a potential drug-repurposing strategy for slowing CKD progression by targeting fibrosis at the gene-regulation level.
Lifestyle and Kidney Health
Exercise May Help Slow Artery Calcification in Chronic Kidney Disease
This cross-sectional study analyzed 571 adults with chronic kidney disease (CKD) from the NHANES 2013–2014 database to investigate whether physical activity is associated with abdominal aortic calcification (AAC), a marker of vascular disease and cardiovascular risk.
Researchers found that both greater weekly exercise time and higher physical activity intensity (measured in metabolic equivalent tasks, or METs) were independently associated with less abdominal aortic calcification.
Every additional hour of physical activity per week was linked to a 1% lower prevalence of AAC, while participants with the highest activity levels had a 29% lower prevalence of vascular calcification compared with inactive individuals.
These associations remained significant after adjusting for traditional cardiovascular and CKD-related risk factors.
Why is this important?
Cardiovascular disease is the leading cause of death in people with CKD, and vascular calcification is a major contributor to that risk.
This study suggests that regular physical activity may help reduce the burden of arterial calcification, providing another mechanism by which exercise supports cardiovascular and kidney health.
Although the study cannot prove cause and effect because of its cross-sectional design, it reinforces physical activity as a key component of comprehensive CKD management.
Join us to end the kidney disease epidemic
Environmental Toxin Exposure
Your ZIP Code May Predict Kidney Disease Better Than Your Genes
This study analyzed data from more than 413,000 participants in the All of Us Research Program to determine whether combining social determinants of health with genetic risk could improve prediction of chronic diseases, including chronic kidney disease (CKD).
Researchers integrated over 100 environmental, behavioral, and social factors—such as income, smoking, loneliness, education, and spirituality—with polygenic risk scores.
For CKD and several other chronic diseases, adding these non-genetic factors consistently improved risk prediction, often more than genetic risk scores alone. The effects of genetic and social factors were largely additive, with little evidence that they interacted.
Why is this important?
This study reinforces that genes are only part of the story. Social, behavioral, and environmental factors often have an equal or greater impact on CKD risk than inherited genetics.
It supports a more holistic approach to kidney disease prevention by incorporating social determinants of health into risk assessment, allowing clinicians to identify high-risk individuals earlier and target modifiable factors such as smoking, socioeconomic barriers, social isolation, and lifestyle alongside genetic susceptibility.
Review article of the month
Could Resveratrol Help Protect the Brain in Chronic Kidney Disease?
This narrative review explores the growing evidence linking chronic kidney disease (CKD) to cognitive impairment through disruption of the kidney–brain axis.
The authors describe how uremic toxins, chronic inflammation, oxidative stress, cerebrovascular dysfunction, mitochondrial injury, glymphatic impairment, and Klotho deficiency contribute to declines in memory, attention, and executive function.
The review also examines resveratrol, a naturally occurring polyphenol, as a potential therapeutic strategy. Preclinical studies suggest that resveratrol reduces oxidative stress and neuroinflammation, improves mitochondrial and endothelial function through SIRT1/PGC-1α signaling, and may restore Klotho expression. However, current human studies remain limited and have produced mixed results.
Join here to receive FREE monthly updates on the latest research in Integrative Nephrology and tips on managing kidney disease straight to your inbox.
We would love to hear your feedback. Let us know what you think of these educational materials and if you would like us to focus on specific topics. Please email us at info@inkidney.com.
